Psoriasis Forum Information for authors

Editorial Policies:

Disclaimer | Conflict of Interest | Human/Animal Subjects | Informed Consent | Authorship

Sections & Article Types:

Original Research | Reviews | Practical Therapeutics | Brief Reports & Abstracts | Case Reports | Editorials & Commentary

Manuscript Preparation:

General | Style | Title Page | Abstract | Key Words | Abbreviations & Acronyms

Photographs, Graphic Elements:

Photographs | Figures | Tables



Procedure for Review:

Peer Review | Revisions & Editing


All manuscripts should be sent, preferably by e-mail, as a Microsoft Word document to the Psoriasis Forum editor,

Download these guidelines »

Editorial Policies

Psoriasis Forum is a peer-reviewed specialty journal published by the National Psoriasis Foundation for its professional members and for dermatology and rheumatology specialists. The purpose of the journal is to provide the latest research and practical treatment information about psoriasis and psoriatic arthritis in a concise and easy-to-read format. Medical professionals are invited to submit articles to be considered for publication. Psoriasis Forum bases its policies on the guidelines set forth by the International Committee of Medical Journal Editors.


The National Psoriasis Foundation is a 501(c)(3) lay, patient-driven nonprofit organization with a mission to find a cure for psoriasis and psoriatic arthritis and to eliminate their devastating effects through research, advocacy, and education. Opinions expressed in this publication are those of the author(s) and do not necessarily reflect the view of the National Psoriasis Foundation, its Board of Trustees, or its Medical Board. Only original articles will be considered for publication in Psoriasis Forum. Please do not submit articles that are being submitted to other journals.

Conflict of Interest

Psoriasis Forum requires all authors to acknowledge all funding sources that supported their work as well as all institutional or corporate affiliations of the authors. The title page must also include a publishable statement disclosing any associations, current and over the past 5 years, that might pose a conflict of interest. These include but are not limited to employment, royalties, consulting arrangements with a commercial entity, stock or other equity ownership, stock options, patent licensing arrangements, payments for conducting or publicizing a product or study, or consulting relationships with investment companies. In addition, authors are required to disclose similar associations with companies that make a competing product. When no conflicting or competing interests are present, this should be indicated. The Editors also require the reviewer to disclose any competing interests or conflicts of interest that might interfere with their objectivity (or to recuse oneself from acting as a reviewer). The Editors and members of the editorial staff have registered their competing interests with the National Psoriasis Foundation. The Editors and members of the editorial staff will ensure that all conflicts are appropriately resolved. Conflicts that cannot be appropriately resolved will result in rejection of the manuscript or review. Undisclosed conflicts may result in sanctions to include published statements of retraction or removal of a manuscript from the archived journal table of contents and Medline database.

-- Return to top ↑ --

Special Requirements for Studies Involving Live Human or Animal Subjects

Studies involving live human or animal subjects must have been approved by the authors' Institutional Review Board (IRB) or its equivalent. A copy of the IRB approval letter must be included with the submission or sent to the Psoriasis Forum editor under separate cover. If applicable, IRB approval must be mentioned in the Methods section of all manuscripts. Patients must not be identified by name or initials; numbers should be used. No other information, including clinical photos or family trees from which a patient could be identified, is permitted unless express written permission from the patient or family is provided at the time of manuscript submission. All clinical investigations must have been conducted according to the Declaration of Helsinki principles. If the Methods section is not sufficiently clear, authors may be asked to provide the editors with a copy of IRB-approved research protocols for the use of our reviewers.

-- Return to top ↑ --

Manuscripts reporting the results of experimental investigation on human subjects must include a statement that informed consent was obtained.

-- Return to top ↑ --


Authorship credit should be based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. All authors should meet conditions 1, 2, and 3. All persons designated as authors should qualify for authorship, and all those who qualify should be listed. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. One author should be designated as the corresponding author, with that author's complete address, telephone and fax numbers, and e-mail address provided on the title page. The Psoriasis Forum editor will correspond only with the corresponding author.

-- Return to top ↑ --

Sections and Article Types

Manuscripts submitted to the Psoriasis Forum should be of general interest to researchers and medical professionals specializing in psoriatic disease research and patient care. Articles are typically 900 to 3,000 words long, but longer articles will be considered.

-- Return to top ↑ --

Reports of Original Research

Original, in-depth clinical and investigative laboratory research papers focused on the fundamental cause and treatment of psoriatic diseases.

-- Return to top ↑ --


Reviews of literature, clinical trials or patterns appearing in cases of psoriasis and psoriatic arthritis pertinent to factors such as the cause, diagnosis, prognosis or therapy of these diseases.

-- Return to top ↑ --

Practical Therapeutics

In-depth review of a therapeutic modality or treatment procedure for the treatment of psoriasis or psoriatic arthritis.

-- Return to top ↑ --

Brief Reports and Abstracts

Brief clinical observations, reports of studies or evaluations that are unique to the care of psoriasis or psoriatic arthritis.

-- Return to top ↑ --

Case Reports

Brief individual cases of psoriasis or psoriasis treatment of unusual interest.

-- Return to top ↑ --

Editorials and Commentaries

Brief, provocative, opinionated communications on issues pertinent to the treatment and care of psoriasis or psoriatic arthritis.

-- Return to top ↑ --

Manuscript Preparation


Only original manuscripts that have not been submitted elsewhere for publication will be considered for publication. The original page-numbered copy of the manuscript must be double-spaced. Please line-number all manuscripts. Manuscripts must be typed, double-spaced, with 1-inch or larger margins throughout, including title page, text, references, legends for illustrations and tables. The Psoriasis Foundation encourages authors to submit relevant graphic elements, such as photographs, charts, tables and illustrations. Authors are responsible for seeking permissionstructured in to republish above-named graphic elements that have been previously published.

-- Return to top ↑ --


Manuscripts must conform to acceptable English usage. Consult the latest edition of The Chicago Manual of Style by The University of Chicago Press or the Manual of Style by the American Medical Association for current usage. Abbreviations must be limited primarily to those in general usage. Weights and measurements must be expressed in metric units. Temperatures must be expressed in degrees centigrade.

-- Return to top ↑ --

Title page

The title page shall include: (1) the title, (2) authors' names, (3) authors' highest earned academic degrees, (4) institutional affiliations and locations, (5) corresponding author information, (6) statement of funding sources and any authors' conflicts of interest and, (7) word count, figure count and number of references.

-- Return to top ↑ --


All articles must be accompanied by an abstract not exceeding 150 words. The abstract should concisely summarize the major points and purpose of the manuscript and its key conclusions. If appropriate, abstract should be structured into sections: Background, Objective, Methods, Results, Conclusion. The abstract should not contain any references.

-- Return to top ↑ --

Key Words

A list of five to eight key words should appear after the abstract.

-- Return to top ↑ --

Abbreviations and Acronyms

Only standard abbreviations are to be used. Consult Scientific Style and Format by the Council of Science Editors or the Manual of Style by the American Medical Association. Abbreviations in the title are not acceptable, and they should be avoided in the abstract. A laboratory or chemical term or a disease process must be spelled out on first reference, with the acronym or abbreviation following in parentheses. The abbreviation or acronym should be used thereafter except in headlines.

-- Return to top ↑ --

Photographs, Graphic Elements


Photographs must be at least 3 inches wide at 300 DPI (minimum of 900 x 600 pixels) and submitted as a .jpeg or .tiff file. Please include file extensions when naming and saving files. Photographic prints or slides may be submitted, but digital files are preferred. Prints and slides must be clearly marked with the top indicated. Microsoft PowerPoint slides are NOT acceptable.

-- Return to top ↑ --


Figures must be submitted in electronic format. Figures must be cited in the text and numbered in order of mention. Figures must be numbered consecutively (i.e., 1, 2, 3). Multi-part figures must be marked clearly (e.g., 1A, 1B, 1C). They must measure between 4 and 6 inches wide and created with vector software such as Adobe Illustrator. Preferably, figures should be attached as separate documents, in addition to embedding them into Word documents. Figures may be saved as .eps, .ai (version CS3) or PDF files—please include file extensions when naming and saving files. Fonts must be typed in Arial or changed to outlines. Figures created in Microsoft Word, PowerPoint, or Excel are NOT acceptable.

-- Return to top ↑ --


Tables may be included in the body of text in a Word document. They should be numbered consecutively (i.e., 1, 2, 3,).

-- Return to top ↑ --


Try to limit references to those that are essential or most relevant. Number references in the order they appear in the text. In text, tables and legends, indicate references with superscript Arabic numerals. When listing references, abbreviate names of journals according to Index Medicus. Please include full page range. Questions about references should be addressed to

List the first six authors; when there are more than six authors, list the first three authors followed by et al. Do not list only the first author followed by et al.

-- Return to top ↑ --

Examples of references

Journal articles
Landells I, Searles G, Shear N, Bissonnette R. Clinical experience with alefacept in canadian patients with psoriasis: The amevive wisdom acquired from real-world evidence (AWARE) study. Psoriasis Forum. 2009;40(2):4-14.

Menter A, Stoff B. Psoriasis. London: Manson Publishing Ltd; 2010.

Chapters in Books
Callis Duffin K, Krueger GG. Topical agents in the treatment of moderate-to-severe psoriasis. In: Koo YM, Lee CS, Lebwohl MG, Weinstein GD, Gottlieb A, editors. Moderate to severe psoriasis, 3rd ed. New York: Informa Healthcare USA; 2009. pp. 209-15.

Electronic Media
Marchettti A, Feldman SR, Kimball AB, et al. Treatments for mild-to-moderate recalicitrant plaque psoriasis: Expected clinical and economic outcomes for first-line and second-line care. Dermatology Online Journal. Available at: Accessed July 28, 2010.

Articles Published Online Ahead of Print
Wilson RL, Feldman SR. Physician performance measures in dermatology. J Am Acad Dermatol. doi:10.1016/j.jaad.2010.04.018. Published online August 1, 2010.

-- Return to top ↑ --

Procedure for review

Peer Review

Psoriasis Forum employs a confidential and anonymous peer review process to evaluate submitted papers for possible publication. The editorial staff will review the manuscript and will usually send it to at least two reviewers. Reviewers will pay particular attention to scientific accuracy, relevance, novelty, importance, appropriate style, whether the article would be of general interest to medical professionals and researchers focused on psoriasis or psoriatic arthritis.

-- Return to top ↑ --

Revisions and Editing

Some degree of manuscript revision should be expected and regarded as constructive. A request to submit a revised manuscript does not guarantee that it will be accepted; rather this means only that it will be reconsidered, perhaps after additional peer review. The final editorial decision rests not only on the validity of the report and the opinions of the reviewers, but also on the editors' judgment of the article's novelty, clarity, importance and likely degree of interest to the readership.

-- Return to top ↑ --


Authors may request up to five copies of the journal, to be mailed upon publication, subject to availability. Reprints of specific articles may also be requested in PDF format. To request a copy or reprint, send an e-mail to, specifying the title and issue in which the article was published and the name and address to whom the reprint should be sent.

-- Return to top ↑ --